5 years ago

Freeline Secures €106 Million to Advance Curative Gene Therapies

  • British biotech startup Freeline has raised €106 million in an extended Series C funding round

  • The round was led by Novo Holdings A/S, Eventide Asset Management, and Wellington Management Company, with participation from Syncona and others

  • The funding will be used to advance Freeline's lead gene therapy programs for Hemophilia B and Fabry Disease, as well as to further develop its proprietary gene therapy platform and expand manufacturing capabilities.

      • ProblemHealthcare

      "Chronic systemic diseases, particularly liver-based ones, often lack effective cures and leave patients with limited options."

      Solution

      "Freeline develops curative gene therapies using next-generation AAV technology to provide long-term relief and potential cures for patients suffering from chronic liver diseases."

      Covered on